The Evolving Role of TKIs in First-line Treatment of Advanced HCC

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:Atezolizumab plus bevacizumab as the current standard of careContraindications to atezolizumab plus bevacizumabThe current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinomaOngoing clinical trials in the first-line settingPresenters:  Josep M. Llovet, MD, PhD, FAASLDProfessor of MedicineDirector, Mount Sinai Liver Cancer ProgramDivision of Liver DiseasesMount Sinai School of MedicineNew York, NYProfessor of ResearchLiver Unit, IDIBAPSHospital Clinic BarcelonaBarcelona, SpainUniv. Prof. Markus Peck-Radosavljevic, MD, MBAProfessor of Medicine, Medical University of ViennaVienna, AustriaDepartment Chair, Innere Medizin and GastroenterologieKlinikum Klagenfurt am WörtherseeKlagenfurt am Wörthersee, AustriaLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.